on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Launches Equine Insulin Assay on TRUFORMA Platform
Zomedica Corp., a veterinary health company, has introduced its latest equine-focused assay for insulin in equine plasma on the TRUFORMA In-Clinic Biosensor Testing Platform. This launch aims to assist veterinarians in diagnosing Equine Metabolic Syndrome (EMS) and Pituitary Pars Intermedia Dysfunction (PPID), potentially serious health issues in horses.
The TRUFORMA Insulin assay enables quick detection of insulin levels, providing results in 18 minutes. This rapidity aids veterinarians in making immediate treatment decisions, bypassing the delays associated with reference laboratories. The assay is available for use in various clinical environments, offering flexibility for equine practitioners.
The combination of TRUFORMA's insulin and eACTH assays provides comprehensive insights into a horse's risk of laminitis, a severe consequence of insulin dysregulation if left untreated. This new diagnostic tool joins Zomedica's portfolio of innovative products designed to enhance veterinary care.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news